375 related articles for article (PubMed ID: 30447300)
21. Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease.
Wang SA; Galili N; Cerny J; Sechman E; Chen SS; Loew J; Liu Q; Fadare O; Hasserjian R; Jones D; Qawi H; Woda B; Raza A
Am J Clin Pathol; 2006 Nov; 126(5):789-97. PubMed ID: 17050076
[TBL] [Abstract][Full Text] [Related]
22. Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease.
Boiocchi L; Espinal-Witter R; Geyer JT; Steinhilber J; Bonzheim I; Knowles DM; Fend F; Orazi A
Mod Pathol; 2013 Feb; 26(2):204-12. PubMed ID: 23018876
[TBL] [Abstract][Full Text] [Related]
23. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
[TBL] [Abstract][Full Text] [Related]
24. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.
Tefferi A; Lasho TL; Huang J; Finke C; Mesa RA; Li CY; Wu W; Hanson CA; Pardanani A
Leukemia; 2008 Apr; 22(4):756-61. PubMed ID: 18216871
[TBL] [Abstract][Full Text] [Related]
25. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
26. JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.
Barosi G; Poletto V; Massa M; Campanelli R; Villani L; Bonetti E; Viarengo G; Catarsi P; Klersy C; Rosti V
PLoS One; 2013; 8(3):e59791. PubMed ID: 23555782
[TBL] [Abstract][Full Text] [Related]
27. Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden.
Nussenzveig RH; Pham HT; Perkins SL; Prchal JT; Agarwal AM; Salama ME
Leuk Lymphoma; 2016; 57(6):1429-35. PubMed ID: 26419289
[TBL] [Abstract][Full Text] [Related]
28. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
29. JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.
Catarsi P; Rosti V; Morreale G; Poletto V; Villani L; Bertorelli R; Pedrazzini M; Zorzetto M; Barosi G;
PLoS One; 2015; 10(1):e0116636. PubMed ID: 25617626
[TBL] [Abstract][Full Text] [Related]
30. JAK2
Strati P; Benton CB; Manshouri T; Zhang Y; Bove JE; Sanchez-Petitto G; Verstovsek S
Leuk Res; 2017 Dec; 63():53-55. PubMed ID: 29101828
[TBL] [Abstract][Full Text] [Related]
31. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
32. The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia.
Moon Y; Kim MH; Kim HR; Ahn JY; Huh J; Huh JY; Han JH; Park JS; Cho SR
Ann Lab Med; 2018 Sep; 38(5):481-483. PubMed ID: 29797820
[TBL] [Abstract][Full Text] [Related]
33. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
[TBL] [Abstract][Full Text] [Related]
34. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
He ZP; Tian HY; Tan M; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
[TBL] [Abstract][Full Text] [Related]
35. How I Diagnose Primary Myelofibrosis.
Prakash S; Orazi A
Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
[TBL] [Abstract][Full Text] [Related]
36. Chronic myelomonocytic leukemia: The role of bone marrow biopsy immunohistology.
Orazi A; Chiu R; O'Malley DP; Czader M; Allen SL; An C; Vance GH
Mod Pathol; 2006 Dec; 19(12):1536-45. PubMed ID: 17041567
[TBL] [Abstract][Full Text] [Related]
37. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
[TBL] [Abstract][Full Text] [Related]
38. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH; Rajan R; Emadi A
Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous myelofibrosis with JAK2 V617F mutation: metastasis, not merely extramedullary hematopoiesis!
Fraga GR; Caughron SK
Am J Dermatopathol; 2010 Oct; 32(7):727-30. PubMed ID: 20859081
[TBL] [Abstract][Full Text] [Related]
40. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]